Evidence map›Paper›PMID 35644004›Full record

ArticleMolecular biology reports2022

MicroRNA-141-3p attenuates oxidative stress-induced hepatic ischemia reperfusion injury via Keap1/Nrf2 pathway.

Tingting Li, Qingsong Chen, Jiangwen Dai, Zuotian Huang, Yunhai Luo, Tong Mou, Junliang Pu, Hang Yang, Xufu Wei, Zhongjun Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Tingting LiDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 YouYi Road, YuZhong District, Chongqing, 400016, China.
Qingsong ChenDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 YouYi Road, YuZhong District, Chongqing, 400016, China.
Jiangwen DaiDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 YouYi Road, YuZhong District, Chongqing, 400016, China.
Zuotian HuangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 YouYi Road, YuZhong District, Chongqing, 400016, China.
Yunhai LuoDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 YouYi Road, YuZhong District, Chongqing, 400016, China.
Tong MouDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 YouYi Road, YuZhong District, Chongqing, 400016, China.
Junliang PuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 YouYi Road, YuZhong District, Chongqing, 400016, China.
Hang YangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 YouYi Road, YuZhong District, Chongqing, 400016, China.
Xufu Wei *Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 YouYi Road, YuZhong District, Chongqing, 400016, China.
Zhongjun Wu *Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 YouYi Road, YuZhong District, Chongqing, 400016, China. wzjtcy@126.com.ORCID http://orcid.org/0000-0002-1627-0633
The Affiliated Yongchuan Hospital of Chongqing Medical University · CN

Funding

National Natural Science Foundation of China 81703063National Natural Science Foundation of China 81873592Natural Science Foundation of Chongqing cstc2018jscx-msybX0133
6 · The paper itself

Abstract

backgroundHepatic ischemia reperfusion injury (IRI) is a major factor affecting the prognosis of liver transplantation through a series of severe cell death and inflammatory responses. However, the potential role of miR-141-3p in hepatic IRI is currently unknown.

methodsWe collected the serum of liver transplantation patients to study the relationship between miR-141-3p and liver injury. A mouse hepatic IRI model was established to measure hepatic dysfunction and cell apoptosis. MiR-141-3p mimic and inhibitor were transfected into hepatocytes to explore the characteristics of hypoxia/reoxygenation (H/R), a classical hepatic IRI in vitro model.

resultsWe found that miR-141-3p levels were negatively correlated with alanine aminotransferase (ALT)/aspartate aminotransferase (AST) in liver transplantation patients. The results demonstrated that miR-141-3p was decreased in mouse liver tissue after hepatic IRI in mice and in hepatocytes after H/R. Overexpression of miR-141-3p directly decreased Kelch-like ECH-associated protein 1 (Keap1) levels and attenuated cell apoptosis in vivo and in vitro, while inhibition of miR-141-3p facilitated apoptosis. Further experiments revealed that overexpression of miR-141-3p also attenuated oxidative stress-induced damage in hepatocytes under H/R conditions.

conclusionsOur results indicate that miR-141-3p plays a major role in hepatic IRI through the Keap1 signaling pathway, and the present study suggests that miR-141-3p might have a protective effect on hepatic IRI to some extent.

Indexed as

Liver DiseasesMicroRNAsReperfusion InjuryAnimalsApoptosisDisease Models, AnimalHypoxiaIschemiaKelch-Like ECH-Associated Protein 1LiverMiceNF-E2-Related Factor 2Oxidative StressKeap1 protein, mouseKelch-Like ECH-Associated Protein 1MicroRNAsMirn141 microRNA, mouseNfe2l2 protein, mouseNF-E2-Related Factor 2ApoptosisHepatic ischemia reperfusion injuryKeap1/Nrf2/HO-1MiR-141-3pReactive oxygen species

Identifiers

PMID35644004
OpenAlexW4281993269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.